Zevra Therapeutics (ZVRA) Cash from Operations (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Cash from Operations of 6142000.0 for Q1 2026, up 11.35% on a QoQ basis from 5516000.0 in Q4 2025, and up 174.7% year-over-year from 2235877.27 in Q1 2025.
Zevra Therapeutics (ZVRA) Cash from Operations (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Cash from Operations history runs 13 years deep, the most recent figure standing at 6142000.0 for Q1 2026.
- Quarterly Cash from Operations rose 174.7% year-over-year to 6142000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12766000.0 (up 120.68% YoY) and the FY2025 annual result came in at 1598000.0, up 97.71% from the prior year.
- Cash from Operations was 6142000.0 for Q1 2026 at Zevra Therapeutics, up from 5516000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 6142000.0 in Q1 2026 and bottomed at 19109000.0 in Q2 2024.
- A 5-year average of 6904294.12 and a median of 4628000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 426.18% — and 2026, when it soared 174.7%.
- Zevra Therapeutics' Cash from Operations stood at 4462000.0 in 2022, then sank by 262.12% to 16158000.0 in 2023, then fell by 0.57% to 16250000.0 in 2024, then surged by 133.94% to 5516000.0 in 2025, then increased by 11.35% to 6142000.0 in 2026.
- Business Quant data shows ZVRA's Cash from Operations at 6142000.0 in Q1 2026, 5516000.0 in Q4 2025, and 4709000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 6.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.14 Mn |
| Mar 31, 2026 | 6.14 Mn |
| Dec 31, 2025 | 5.52 Mn |
| Dec 31, 2025 | 5.52 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Mar 31, 2025 | -8.22 Mn |
| Mar 31, 2025 | -8.22 Mn |
| Dec 31, 2024 | -16.25 Mn |
| Dec 31, 2024 | -16.25 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Jun 30, 2024 | -19.11 Mn |
| Jun 30, 2024 | -19.11 Mn |
| Mar 31, 2024 | -16.17 Mn |
| Mar 31, 2024 | -16.17 Mn |
| Dec 31, 2023 | -16.16 Mn |
| Dec 31, 2023 | -16.16 Mn |